Compare Stocks → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison TSE:APSNYSEARCA:COMCVE:IGXCVE:NVH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPSAptose BiosciencesC$1.68-1.2%C$2.16C$1.68▼C$11.40C$26.39M1.448,831 shs2,000 shsCOMDirexion Auspice Broad Commodity Strategy ETF$29.230.0%$28.47$27.56▼$31.62$260.15M0.1946,994 shs61,266 shsIGXIntelGenx TechnologiesC$0.58+1.8%C$0.58C$0.17▼C$0.85C$87.32MN/A56,279 shs11,848 shsNVHNovoheartC$0.53+1.9%C$0.53C$0.26▼C$0.72C$99.98MN/A33,593 shs23,066 shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPSAptose Biosciences+0.59%-5.56%-18.66%-33.59%+153.73%COMDirexion Auspice Broad Commodity Strategy ETF-0.75%-1.52%+4.21%+5.65%-6.04%IGXIntelGenx Technologies0.00%0.00%0.00%0.00%0.00%NVHNovoheart0.00%0.00%0.00%0.00%0.00%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPSAptose BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACOMDirexion Auspice Broad Commodity Strategy ETFN/AN/AN/AN/AN/AN/AN/AN/AIGXIntelGenx TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ANVHNovoheartN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPSAptose BiosciencesN/AN/AN/AN/ACOMDirexion Auspice Broad Commodity Strategy ETF0.00N/AN/AN/AIGXIntelGenx TechnologiesN/AN/AN/AN/ANVHNovoheartN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPSAptose BiosciencesN/AN/AC$1.05 per share1.60C$1.03 per shareN/ACOMDirexion Auspice Broad Commodity Strategy ETFN/AN/AN/AN/AN/AN/AIGXIntelGenx TechnologiesC$1.75M49.95C$0.08 per share7.16C$0.05 per share12.89NVHNovoheartC$423.50K236.08C$0.07 per share7.46C$0.12 per share4.34Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPSAptose Biosciences-C$51.21M-C$10.49N/A∞N/AN/A-225.00%-102.23%5/13/2024 (Estimated)COMDirexion Auspice Broad Commodity Strategy ETFN/AN/A0.00∞N/AN/AN/AN/AN/AIGXIntelGenx TechnologiesN/A-C$0.08N/A∞N/AN/AN/AN/AN/ANVHNovoheartN/A-C$0.04N/A∞N/AN/AN/AN/AN/ALatest APS, IGX, NVH, and COM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2024Q4 2023APSAptose Biosciences-C$1.98-C$1.96+C$0.02-C$1.96N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPSAptose BiosciencesN/AN/AN/AN/AN/ACOMDirexion Auspice Broad Commodity Strategy ETF$2.538.66%N/AN/AN/AIGXIntelGenx TechnologiesN/AN/AN/AN/AN/ANVHNovoheartN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPSAptose Biosciences14.270.785.41COMDirexion Auspice Broad Commodity Strategy ETFN/AN/AN/AIGXIntelGenx Technologies164.622.772.69NVHNovoheart27.626.136.05OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPSAptose Biosciences9.80%COMDirexion Auspice Broad Commodity Strategy ETFN/AIGXIntelGenx TechnologiesN/ANVHNovoheartN/AInsider OwnershipCompanyInsider OwnershipAPSAptose Biosciences20.20%COMDirexion Auspice Broad Commodity Strategy ETFN/AIGXIntelGenx TechnologiesN/ANVHNovoheartN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPSAptose Biosciences3115.71 millionN/ANot OptionableCOMDirexion Auspice Broad Commodity Strategy ETFN/A8.90 millionN/ANot OptionableIGXIntelGenx Technologies48150.55 millionN/ANot OptionableNVHNovoheartN/A188.64 millionN/ANot OptionableAPS, IGX, NVH, and COM HeadlinesSourceHeadlineBuilding miniature hearts to improve clinical trialsbiotechniques.com - June 22 at 8:37 AMLeaked Documents Reveal Cybertruck's Glaring Design Flawsfuturism.com - June 14 at 5:37 PM067570.KQ - NVH Korea Inc.finance.yahoo.com - June 12 at 1:23 PMNBA Playoffs: Jokic set for 1st NBA Finals, Heat try to clinch East crownwhio.com - May 26 at 4:32 AMNBA Playoffs: Nuggets become 1st team to reach this year's NBA final fourwftv.com - May 18 at 2:11 AMNVH Korea Inc (067570)uk.investing.com - February 21 at 1:07 PMNovoheart Holdings Inc (NVH)investing.com - July 22 at 11:31 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to ComeConsumer Sentiment Highest Since 2021, 3 Stocks Leading the WayApril 1, 2024 9:25 AMView Consumer Sentiment Highest Since 2021, 3 Stocks Leading the WayWhat is the Nasdaq? Complete Overview with HistoryApril 16, 2024 8:00 AMView What is the Nasdaq? Complete Overview with HistoryAll Headlines Company DescriptionsAptose BiosciencesTSE:APSAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Direxion Auspice Broad Commodity Strategy ETFNYSEARCA:COMThe Direxion Auspice Broad Commodity Strategy ETF (COM) is an exchange-traded fund that is based on the Auspice Broad Commodity index. The fund tracks a broad-market index consisting of 12 commodity futures contracts, weighted by historical volatility, which can toggle to cash based on momentum. The fund will also hold short-term fixed income securities as collateral. COM was launched on Mar 30, 2017 and is managed by Direxion.IntelGenx TechnologiesCVE:IGXIntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine. The company's products under development comprise INT0004/2006, an antidepressant; INT0046/2018 for adult use; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid addition; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, and INT0053/2020. The company has licensing, development, and supply agreement with Tilray, Inc. and Gensco Pharma; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.NovoheartCVE:NVHNovoheart Holdings Inc. operates as a stem cell biotechnology company in the United States. The company offers an array of next-generation human heart tissue prototypes. It provides MyHeart platform products, including human pluripotent stem cell-derived cardiomyocytes, human ventricular cardiac anisotropic sheet assays, and human ventricular cardiac tissue strips assays. The company also offers screening and phenotyping services; and consultation services, including mapping and designing preclinical studies that involve human embryonic or induced pluripotent stem cell-derived cardiomyocytes, prototyping custom bioreactor designs, and developing custom software for streamlining of screening platforms and analysis of acquired data. Novoheart Holdings Inc. has a collaboration with AstraZeneca to develop human-specific in vitro functional model of heart failure with preserved ejection fraction. The company is based in Vancouver, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.